Funding for this research was provided by:
Received: 26 October 2021
Accepted: 14 December 2021
First Online: 22 December 2021
: The study was conducted according to Helsinki criteria and received approval by the local ethics committee of the Medical Center – University of Freiburg, Faculty of Medicine (EK FR 536/19). Written informed consent was obtained from each patient.
: Not applicable.
: RD reports lecture fees from Roche and Alexion and travel grants by Biogen.AS declares no conflict of interest.DC declares no conflict of interest.PE declares no conflict of interest.JSC declares no conflict of interest.SR reports consulting and lecture fees, grant and research support from Bayer Vital GmbH, Biogen, Celgene, Merck Serono, Novartis, Sanofi- Aventis, Genzyme, Roche and Teva; founding executive board member of ravo Diagnostika GmbH Freiburg.